TY - JOUR T1 - Late-breaking abstract: Improving cell mediated immunity to non-typeable haemophilus influenzae in children with chronic suppurative lung disease JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P1227 AU - John Upham AU - Susan Pizzutto AU - Stephanie Yerkovich AU - Wayne Thomas AU - Belinda Hales AU - Anne Chang Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P1227.abstract N2 - Finding an effective vaccine to protect against non-typeable Haemophilus influenzae (NTHi) is an important goal in bronchiectasis & chronic suppurative lung disease (CSLD). NTHi infection is common in both conditions and impaired cell-mediated immunity against NTHi has been documented. Aim: Determine if a H. influenzae protein D containing conjugate vaccine improves cytokine responses to NTHi in children with CSLD. Methods: 108 children with CSLD and 32 healthy children (median age 2 yrs) were included. Those who received the 10-valent pneumococcal H. influenzae protein D conjugate vaccine (PHiD-CV) were compared with those who received multi-valent pneumococcal vaccine without protein D. Blood mononuclear cells were cultured with live NTHi. Results: Cells from CSLD children who had received 3 doses of PHiD-CV produced significantly more interferon gamma (IFN median 939; IQ range 247-2142 pg/ml) than cells from children who had received the alternative vaccines (median 338; IQ range 108-938 pg/ml; p=0.007). Importantly, the amount of IFN produced by cells from CSLD children receiving 3 doses of PHiD-CV approached that seen with healthy children. Having received 3 doses of PHiD-CV was also associated with small but significant increases in IL-13 and IL-5 (p < 0.001 and p=0.007 respectively). Plasma protein D-specific IgG1 levels correlated with the number of PHiD-CV doses (p=0.02). Conclusions: Vaccination with PHiD-CV augments NTHi-specific cell mediated immunity in children with CSLD. Clinical trials are now warranted to determine whether these effects translate into improved protection against NTHi infections in children with CSLD.≥γγ≥≥ ER -